Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
Volume 1866, Issue 2, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbalip.2020.158854
Keywords
Docosahexaenoic acid; Palmitoylethanolamide; Short chain fatty acids; Autotaxin; Eicosanoids; SPM
Ask authors/readers for more resources
Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are chronic conditions that are difficult to treat. Research has shown that lipid mediators play a crucial role in inflammation and immunity, and can have a significant impact on the pathophysiology of IBDs.
Inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, are lifelong diseases that remain challenging to treat. IBDs are characterized by alterations in intestinal barrier function and dysregulation of the innate and adaptive immunity. An increasing number of lipids are found to be important regulators of inflammation and immunity as well as gut physiology. Therefore, the study of lipid mediators in IBDs is expected to improve our understanding of disease pathogenesis and lead to novel therapeutic opportunities. Here, through selected examples - such as fatty acids, specialized proresolving mediators, lysophospholipids, endocannabinoids, and oxysterols - we discuss how lipid signaling is involved in IBD physiopathology and how modulating lipid signaling pathways could affect IBDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available